Focus Partners Advisor Solutions LLC Makes New $638,000 Investment in Illumina, Inc. $ILMN

Key Points

• Focus Partners Advisor Solutions LLC has acquired 8,040 shares of Illumina, Inc. valued at approximately $638,000, marking a significant investment during the first quarter.
• Illumina reported a quarterly earnings per share of $1.19, exceeding expectations, although its revenue of $1.06 billion fell short of estimates and represented a 4.8% decline year-over-year.
• Analysts exhibit mixed sentiment with six research analysts rating Illumina as a Buy while the consensus target price is set at $123.06, indicating cautious optimism for the company's stock performance.

Focus Partners Advisor Solutions LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,040 shares of the life sciences company's stock, valued at approximately $638,000.

Other institutional investors have also recently bought and sold shares of the company. Diversified Trust Co acquired a new stake in Illumina during the first quarter worth $355,000. State of Alaska Department of Revenue boosted its stake in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock worth $1,469,000 after buying an additional 445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Illumina by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock worth $15,803,000 after buying an additional 9,252 shares in the last quarter. Merit Financial Group LLC boosted its stake in Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock worth $1,034,000 after buying an additional 10,105 shares in the last quarter. Finally, Citigroup Inc. boosted its stake in Illumina by 13.5% during the first quarter. Citigroup Inc. now owns 150,764 shares of the life sciences company's stock worth $11,962,000 after buying an additional 17,985 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ILMN shares. Wall Street Zen downgraded shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Robert W. Baird boosted their target price on shares of Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Daiwa America downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Finally, Citigroup downgraded shares of Illumina from a "hold" rating to a "strong sell" rating and reduced their target price for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $123.06.

Illumina Price Performance

NASDAQ ILMN traded up $1.25 on Friday, hitting $98.93. 1,520,102 shares of the company were exchanged, compared to its average volume of 1,311,242. The firm has a 50 day moving average of $99.63 and a two-hundred day moving average of $88.45. The company has a market cap of $15.21 billion, a P/E ratio of 12.52, a P/E/G ratio of 2.22 and a beta of 1.43. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.